Kidney Int: Dapagliflozin and Prevention of Adverse Outcomes of Chronic Kidney Disease (DAPA-CKD) Pre-designated Analysis of Randomized Controlled Trial Study on the Incidence of Sudden Decline in Renal Function

Approximately 13 million people worldwide suffer from acute kidney injury (AKI) every year, mainly in hospitalized patients

Severe chronic kidney disease (CKD) is associated with an increased risk of AKI.

Methods: DAPA-CKD is a randomized, double-blind, placebo-controlled trial with an average follow-up time of 2.

²

Results: There were 63 people (2.

Figure 1 shows the cumulative incidence curve of a sudden decline in renal function (serum creatinine at least doubles between median visits at 100-day intervals)

Figure 1 shows the cumulative incidence curve of a sudden decline in renal function (serum creatinine at least doubles between median visits at 100-day intervals)

Figure 2 The forest plot shows the incidence of sudden declines in renal function by subgroup (serum creatinine at least doubled during visits at an average 100-day interval)

Figure 2 The forest plot shows the incidence of sudden declines in renal function by subgroup (serum creatinine at least doubled during visits at an average 100-day interval)

Table 1 Factors related to the event of sudden decline in renal function

Table 1 Factors related to the event of sudden decline in renal function

Table 2 The relationship between sudden decline in renal function and ESKD/kidney death and mortality

Table 2 The relationship between sudden decline in renal function and ESKD/kidney death and mortality

Figure 3 The modulating effect of dapagliflozin treatment on end-stage renal disease (ESKD) or all-cause death with a sudden decline in renal function

Figure 3 The modulating effect of dapagliflozin treatment on end-stage renal disease (ESKD) or all-cause death with a sudden decline in renal function

In patients with CKD and large proteinuria, dapagliflozin reduces the risk of sudden decline in renal function

Heerspink HJ, Cherney D, Postmus D,et al.

A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function

in this message